Notable Labs

Notable Labs EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Notable Labs (NTBLQ) as of Nov 11, 2026 is 0.84. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 0.66 — a change of 27.65% (higher).

EV/OCF

0.84

YoY

27.65%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Notable Labs is 2023 0.84 . EV/OCF (Enterprise Value to Operating Cash Flow) of Notable Labs was 2022 0.66 . It decreases by 27.65% higher compared to the previous year.

The Notable Labs EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2016
3.37 USD
Jan 1, 2017
14.33 USD
Jan 1, 2018
3.17 USD
Jan 1, 2019
2.75 USD
Jan 1, 2020
1.29 USD
Jan 1, 2021
2.13 USD
Jan 1, 2022
0.66 USD
Jan 1, 2023
0.84 USD
The Notable Labs EV/OCF history
YEAREV/OCFYoY
0.84+27.65%
0.66-69.17%
2.13+64.83%
1.29-53.13%
2.75-13.08%
3.17-77.89%
14.33+324.59%
3.37+19.90%
2.81+4.83%
2.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Notable Labs is 0.84 in 2023.

EV/OCF (Enterprise Value to Operating Cash Flow) of Notable Labs changed from 0.66 to 0.84, representing a 27.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Notable Labs since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Notable Labs with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Notable Labs

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Notable Labs